lans have been released by The UK Medicines and Healthcare products Regulatory Agency (MHRA) to launch an
Early Access to Innovative Devices Programme, a new pathway designed to bring safe, effective medical technologies to patients more quickly. Built on lessons from the Innovative Devices Access Pathway (IDAP) pilot, the new scheme will allow promising medical devices to be used under time-limited, conditional authorisation, especially where they meet unmet clinical needs such as in diagnostics. Manufacturers must continue generating real-world evidence on safety and performance throughout this period. For patients, this means earlier access to
potentially life-changing equipment, but for MedTech innovators the programme offers structured regulatory support, clearer milestones and a faster route to market. This, however, then brings new challenges.
Devices will still need to satisfy rigorous safety standards and be practical in real-world settings – for example, they will be need to be robust, intuitive, and compact enough for home use. However, speed of deployments may mean fewer opportunities for multiple design iterations before a device is placed in patients’ hands. This means the performance of internal
components such as motors becomes even more critical. A failure in a drive system can compromise the entire device, jeopardising its conditional authorisation and limiting the ability to generate the real-world evidence required for full
21
approval. Reliability therefore shifts from being a design aspiration to a fundamental requirement for regulatory and clinical success. This focus on reliability is especially critical in
compact diagnostic devices such as micro-pumps and fluid handling systems. These rely on miniature motors to move fluids precisely to ensure accurate test results in point-of-care devices and portable blood analysers. In the future, this could extend to fully automated home diagnostic kits, wearable monitoring systems for
multiple biomarkers and compact imaging tools that provide rapid, on-the-spot clinical insights.
For this technology to become reality, and for it to work dependably from day one, the drive systems powering these devices must be designed with precision and reliability. Miniature motors used in medical applications are often designed to deliver consistent torque and speed across long operating cycles, while minimising vibration and heat. These are critical factors for both accuracy and patient comfort. High-performance motors may incorporate
features such as precision bearings, advanced magnetic materials, low-friction coatings and compact gearheads to maintain efficiency in small form factors. Careful thermal management and low-noise operation will also be essential to help ensure that devices can run continuously, often in close proximity to the patient, without compromising measurement accuracy or comfort.
For the MHRA’s new programme to become a reality and accelerate the route to market for medical devices, miniature motor technology must act as an enabler of next-generation performance. Collaborating closely with specialist manufacturers to supply motors that enable earlier diagnosis, more effective treatment and improved patient outcomes, will play a key role in supporting the implementation of these new regulations and ultimately bringing innovative solutions to patients more quickly.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
